RxDoctor Payments Data

Carl Hanke, MD

MOHS-Micrographic Surgery · Indianapolis, INNPI 1295771244

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 26.3% of the total.

$96,027in general payments, 2019–2025

Across 329 payments — averaging $291.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$25K
  • Sanofi$24K
  • Regeneron$14K
  • Regeneron Healthcare Solutions, Inc.$11K
  • DUSA Pharmaceuticals, Inc.$6K
  • Biofrontera Inc.$3K
  • plus $12K from 34 others
$1,336,090in research payments, 2019–2025

Across 145 payments — averaging $9214.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1.2M
  • Endo Pharmaceuticals Inc.$78K
  • Biofrontera Bioscience GmbH$54K
  • Biofrontera Inc.$18K

What the payments were for

  • Consulting fees$27,25028%
  • Speaking & faculty fees$53,12755%
  • Travel & lodging$4,8725%
  • Food & beverage$9,50910%
  • Gifts$110%
  • Other$1,2581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,171,038
Medicare patients
1,644
Services billed
4,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErivedgeVismodegib26$247,106
Doxycycline Hyclate362$2,663
Cephalexin437$2,080
Doxycycline Monohydrate61$552
Triamcinolone Acetonide19$164
ValacyclovirValacyclovir Hcl12$126
Azithromycin23$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Erivedge$167$247,10626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few mohs-micrographic surgery providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other mohs-micrographic surgery in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →